quantisnow
FeedTopReportsPricing
⌘K
Live feed
15:58:01·441d
INSIDERFiling
Revance Therapeutics Inc. logo

CMO & Global Therapeutics Lead Hollander David returned 95,212 shares to the company, closing all direct ownership in the company (SEC Form 4)

RVNC· Revance Therapeutics Inc.
Health Care
Original source

Companies

  • RVNC
    Revance Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 29UpdateMizuho$9.00
  • Jan 9UpdateGoldman$8.00
  • Aug 16UpdateExane BNP Paribas$20.00
  • Oct 11UpdateMorgan Stanley$27.00
  • Sep 22UpdateGoldman$33.00
  • Oct 26UpdateBarclays$22.00

Related

  • SEC430d
    SEC Form 15-12G filed by Revance Therapeutics Inc.
  • SEC434d
    Amendment: SEC Form SCHEDULE 13G/A filed by Revance Therapeutics Inc.
  • SEC435d
    SEC Form S-8 POS filed by Revance Therapeutics Inc.
  • SEC435d
    SEC Form S-8 POS filed by Revance Therapeutics Inc.
  • SEC435d
    SEC Form S-8 POS filed by Revance Therapeutics Inc.
  • SEC435d
    SEC Form S-8 POS filed by Revance Therapeutics Inc.
  • SEC435d
    SEC Form S-8 POS filed by Revance Therapeutics Inc.
  • SEC435d
    SEC Form S-8 POS filed by Revance Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022